Latest AFT Pharmaceuticals (NZX:AFT) News

AI cardiology, cancer research and pharma expansion drove the biggest moves in healthcare stocks this week. Investors paid up for fresh funding and regulatory wins, while some raisings and weak trading updates kept pressure on others.

AFT Pharmaceuticals delivered a 22% revenue jump in FY26 to NZD 254.7 million, surpassing profit guidance and expanding its footprint to 87 countries. The company is advancing multiple R&D projects, including a pivotal Phase III injectable iron trial, while targeting over NZD 300 million in revenue for FY27.